Park JW, et al. - In patients with axial spondyloarthritis (axSpA), researchers examined the connection between the extent of tapering tumor necrosis factor inhibitor (TNFi) and the probability of achieving inactive disease. In a nationwide observational cohort, they evaluated 1575 one-year follow-up interval data of 776 patients. Using the generalized estimating equation, the impacts of TNFi tapering on the outcome were analyzed. According to findings, 91.1% of the patients exhibited a high disease activity (ASDAS-CRP ≥ 2.1) at the baseline visit. Findings suggested that mild TNFi tapering has comparable efficacy with the standard-dose treatment for Ankylosing Spondylitis Disease Activity Score-inactive disease achievement in axSpA patients.